Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(11):1673-1676; doi:10.1093/annonc/mdl287
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
lung cancer |
Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis
1 Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
2 Data Centre, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
3 Department of Pathology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
4 Chest Department, Centre Hospitalier Universitaire Calmette, Lille, France
*Correspondence to: Dr T. Berghmans, Institut Jules Bordet, rue Héger-Bordet, 1, B-1000 Brussels, Belgium. Tel: +32-2-541-31-91; Fax: +32-2-534-37-56; E-mail: thierry.berghmans{at}bordet.be
Background: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer.
Methods: Studies evaluating survival and TTF-1 in lung cancer patients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated.
Results: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%–70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41–1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29–0.95).
Conclusion: TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.
Key words: lung cancer, meta-analysis, prognostic factor, survival, systematic review, thyroid transcription factor 1
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. K. Anagnostou, K. N. Syrigos, G. Bepler, R. J. Homer, and D. L. Rimm Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma J. Clin. Oncol., January 10, 2009; 27(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Sculier Prognostic Factors and Implications of Positron Emission Tomography ASCO Educational Book, January 1, 2009; 2009(1): 469 - 472. [Abstract] [Full Text] [PDF]
|
|